Skip to main content

Table 2 Clinical characteristics of the studied patients

From: Impact of vitamin D level in diabetic people with peripheral neuropathy

Item Group A (n = 20) Group B (n = 20) Group C (n = 20) Control group (n = 20) χ2/KWT p-value
n % n % n % n %
Duration of DM (years)
 Mean ± SD 8.95 ± 3.42 8.7 ± 3.63 7.6 ± 2.94 3.6 ± 1.2 14.86 0.001* (HS)
 Median (range) 9 (4–15) 8 (3–17) 7 (3–14) 3 (1–6)
The current hypoglycemic drug
 Insulin 10 50% 8 40% 8 40% 9 45% 4.81 0.850 (NS)
 Glimepiride 3 15% 5 25% 6 30% 5 25%
 Gliclazide 6 30% 3 15% 4 20% 3 15%
 Combined preparation 1 5% 4 20% 2 10% 3 15%
Score of neuropathy (TCSS)
 Mean ± SD 12.25 ± 2.14 7.6 ± 1.09 9.70 ± 2.02 0.95 ± 1.19 63.39 0.000* (HS)
 Median (range) 12.5 (9–15) 8(6–9) 9 (7–14) 0.5 (0–4)
Stage of diabetic foot
 Normal foot 12 60% 20 100% 0 0% 20 10 65.11 0.001* (HS)
 Ulcerated 4 20% 0 0% 17 85% 0 0
 Infected 3 15% 0 0% 2 10% 0 0
 Necrotic 1 5% 0 0% 1 5% 0 0
  1. n: number; %: percentage; χ2: Chi-square test; KWt: Kruskal–Wallis test; HS: highly significant; TCSS: Toronto Clinical Scoring System